Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for MDNA11 (IL-2) in Cold tumors. The expected timing is based on the latest available company guidance and may change.
06/26/26:- ABILITY-1 enrollment completes Q3 2026. ABILITY-1 and NEO-CYT data expected H2 2026. 08/14/26:- ABILITY-1 enrollment is expected to complete in Q3 2026. Updated ABILITY-1 data will be presented at an upcoming conference. NEO-CYT preliminary data is expected in Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.